Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 4:07 AM
Ignite Modification Date:
2025-12-25 @ 4:07 AM
NCT ID:
NCT01118520
Eligibility Criteria:
Inclusion criteria:
Willing and able to give written informed consent
Men or women, aged at least 55 years
With AAA 3 to 5.4 cm in diameter by internal or external measurement according to ultrasound
A systolic BP \<150mmHg (unless they require and are already receiving an ACE-inhibitor or amlodipine 10mg daily).
Exclusion criteria:
Patients who are already required to take either an ACE-inhibitor or a calcium channel blocker or Angiotensin II blocker (ARB) who cannot be converted to diuretic therapy and/ora 5mg dose of amlodipine for control (ie SBP \< 150mmHg) of their BP.
Those with known renal artery stenosis (\>50%), or with a serum creatinine of \>180µmol/L
Those unable to give informed consent
Those too frail to travel for 3-monthly surveillance will be excluded
Any clinically significant medical condition which, in the opinion of the investigator, may interfere with the study results and or reduce life expectancy to \< 2 years
Participation in another trial of an investigational product or device within the previous 30 days
Known allergy or sensitivity to perindopril or amlodipine
Unable or unwilling to comply with the requirements of the study, in the opinion of the investigator.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
55 Years
Study:
NCT01118520
Study Brief:
Protocol Section:
NCT01118520